FacultyFaculty/Author Profile
Margaret Bolce Brivanlou, Ph.D.

Margaret Bolce Brivanlou, Ph.D.

King & Spalding

New York City, NY, USA


Peg Brivanlou is a Partner in King & Spalding’s Intellectual Property, Patent, Trademark and Copyright Litigation practice, specializing in patent prosecution, client counseling, due diligence and patent litigation.  Peg represents clients in the biotechnology and pharmaceutical industries, and investment funds in a variety of intellectual property matters.

With a focus on biologics and small molecule therapeutics, Peg counsels clients regarding immunotherapeutics, cell-based assays and therapies, genomics, bioinformatics, vaccines and small molecule pharmaceuticals. She is experienced in developing patent portfolios, particularly relating to biologics, antibody therapeutics and diagnostics. She also conducts patent invalidity, freedom-to-operate analyses and pre-litigation investigations, including for pre-Hatch-Waxman litigation.

In addition, Peg represents clients on the intellectual property aspects of a wide range of transactions, from technology transfer and out-licensing to multi-million-dollar asset purchases and financings. She conducts due diligence, and negotiates licensing and purchase agreements as well as disclosure documents in connection with public and private financings.

Peg is listed as an IP Star in the 2018/2019 rankings of Managing Intellectual Property.

Margaret Bolce Brivanlou, Ph.D. is associated with the following items:
Web Segment  Web Segment Patenting Biologics—Antibodies, Proteins and Cell-Based Therapies - Developments in Pharmaceutical and Biotech Patent Law 2018, Tuesday, October 30, 2018
MP3 Audio  MP3 Audio Patenting Biologics—Antibodies, Proteins and Cell-Based Therapies - Patenting Biologics—Antibodies, Proteins and Cell-Based Therapies, Tuesday, October 30, 2018
Transcripts  Transcripts Patenting Biologics—Antibodies, Proteins and Cell-Based Therapies - Patenting Biologics—Antibodies, Proteins and Cell-Based Therapies, Tuesday, October 30, 2018
MP4 - Mobile Video Seg  MP4 - Mobile Video Seg Patenting Biologics—Antibodies, Proteins and Cell-Based Therapies - Patenting Biologics—Antibodies, Proteins and Cell-Based Therapies, Tuesday, October 30, 2018
CHB Chapters  CHB Chapters Patenting Biologics—Antibodies, Proteins and Cell-Based Therapies - Developments in Pharmaceutical and Biotech Patent Law 2018, Wednesday, October 31, 2018
United States Patent and Trademark Office, Memorandum, Clarification of Written Description Guidance for Claims Drawn to Antibodies and Status of 2008 Training Materials (February 22, 2018); Subject Matter Eligibility Examples: Life Sciences; United States Patent and Trademark Office, Memorandum, Recent Subject Matter Eligibility Decision: Vanda Pharmaceuticals Inc. v. West-Ward Pharmaceuticals (June 7, 2018) - Developments in Pharmaceutical and Biotech Patent Law 2018, Wednesday, October 31, 2018
On-Demand Web Programs  On-Demand Web Programs Developments in Pharmaceutical and Biotech Patent Law 2018, Wednesday, November 07, 2018, New York, NY
Share
Email

  • FOLLOW PLI:
  • twitter
  • LinkedIn
  • YouTube
  • RSS

All Contents Copyright © 1996-2018 Practising Law Institute. Continuing Legal Education since 1933.

© 2018 PLI PRACTISING LAW INSTITUTE. All rights reserved. The PLI logo is a service mark of PLI.